Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2022-11-14 Interim / Quarterly Rep…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Q3 statement / Q3 financial report 2022
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' covering the period from 1 January to 30 September 2022. It contains detailed financial statements, including the consolidated statement of income, financial position, and cash flow statement, as well as management's analysis of business performance, research and development, and financial position. It is a comprehensive interim report rather than a mere announcement or summary, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-11-14 English
Biotest AG: Biotest reports sales of Euro 361 million in the first nine months of 2022
Earnings Release Classification · 100% confidence The document is a press release dated November 8, 2022, reporting sales and earnings figures for the first nine months of 2022. It explicitly mentions key financial metrics (sales of €361 million, EBIT, EBITDA) for a period shorter than a full year. This aligns perfectly with the definition of an Interim/Quarterly Report (IR). However, the text also contains a crucial statement: "Biotest will publish the complete figures for the first nine months of the 2022 financial year on 14 November 2022." This indicates that the current document is an early announcement or highlight release, not the comprehensive report itself. The definition for Earnings Release (ER) is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. Since this document provides key highlights (sales, EBIT, EBITDA) for the nine-month period and precedes the publication of the 'complete figures', it is best classified as an Earnings Release (ER). The document length (4925 chars) is substantial enough to be more than just a simple RPA, but its content is focused on the initial results announcement. 9M 2022
2022-11-08 English
Biotest AG: Biotest AG opens 14th plasma collection centre in the Czech Republic
Regulatory Filings Classification · 100% confidence The document is a press release dated October 13, 2022, announcing that Biotest AG has opened its 14th plasma collection center in the Czech Republic. It discusses operational expansion, job creation, and the importance of plasma supply for medical products. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is a general corporate announcement regarding business operations and expansion, which fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate news item, as it doesn't align with specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS). Given the content is a standard press release about business operations distributed via EQS News, RNS is the most appropriate fallback.
2022-10-13 English
Biotest AG: Biotest AG opens 13th plasma collection centre in the Czech Republic
Regulatory Filings Classification · 100% confidence The document is a short press release dated September 26, 2022, announcing a specific operational update: Biotest AG opening its 13th plasma collection center in the Czech Republic. It contains company boilerplate information, contact details, and is distributed via EQS News Service. It is not a comprehensive financial report (like 10-K or IR), nor is it a transcript (CT) or a formal voting result (DVA). Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Director's Dealing (DIRS), or Dividend (DIV), it falls best under the general regulatory announcement category, which is RNS (Regulatory Filings), as per the fallback rule and the nature of the announcement being a routine operational update distributed via a news service.
2022-09-26 English
Biotest AG: Biotest AG opens 12th plasma collection centre in the Czech Republic
Regulatory Filings Classification · 100% confidence The document is a short press release dated September 6, 2022, announcing a specific operational update: the opening of Biotest AG's 12th plasma collection center in the Czech Republic. It contains key highlights, company background, and contact information, but it is not a comprehensive financial report (like 10-K or IR) or a transcript (CT). It is a general corporate announcement disseminated via DGAP. Since it doesn't fit the specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (CAP), and it is a general news item about business operations, the most appropriate classification is the general regulatory announcement fallback category, RNS (Regulatory Filings), as it is a 'Corporate News' transmitted by DGAP.
2022-09-06 English
Biotest AG: Biotest achieves an improved adjusted EBIT by 9.8% of EUR 32.4 million in the first half of 2022
Earnings Release Classification · 100% confidence The document is a press release dated August 11, 2022, detailing financial results for the 'first half of 2022'. It explicitly mentions key financial metrics like sales, EBITDA, EBIT, and adjusted EBIT, and provides an outlook for the full year 2022. The presence of 'Half Year Results' as a keyword and the comprehensive nature of the financial summary for a six-month period strongly indicate this is an Interim/Quarterly Report announcement, even though it is presented as a press release. The document concludes by stating, 'The Half Year Report 2022 is available on the company’s website,' suggesting this text is the summary/release of that report. This aligns best with the Interim / Quarterly Report (IR) definition, which covers comprehensive financial reports for periods shorter than a year. It is more detailed than a simple Earnings Release (ER) which usually contains only key highlights. H1 2022
2022-08-11 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.